{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:09:43Z","timestamp":1780470583424,"version":"3.54.1"},"reference-count":84,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Oncolytic viruses (OVs) exploit key hallmarks of cancer to selectively replicate in malignant cells, leading to tumor cell lysis, modulation of the tumor microenvironment, and induction of antitumor immunity. These viral platforms have been engineered to enhance tumor specificity, intratumoral spread, and immunotherapeutic efficacy. Among them, rhabdoviruses, particularly vesiculoviruses, have emerged as promising candidates due to their rapid replication, high titers, and amenability to genetic manipulation. Maraba virus, a recently identified vesiculovirus, is a single-stranded negative-sense RNA virus with a favorable safety profile and minimal pre-existing immunity in humans. It demonstrates selective tumor tropism partly through low-density lipoprotein receptor (LDLR)-mediated entry and impaired antiviral responses in cancer cells. Genetic engineering of the wild-type Maraba virus led to the development of the MG1 strain, characterized by enhanced tumor selectivity, increased replication capacity, and potent cytolytic activity. Preclinical studies have demonstrated its efficacy as a monotherapy, a cancer vaccine vector expressing tumor-associated antigens, and in combination with chemotherapy and immune checkpoint inhibitors. MG1 also reshapes the tumor microenvironment, converting immunologically \u201ccold\u201d tumors into \u201chot\u201d tumors, thereby enhancing immune-mediated tumor clearance. Compared to vesicular stomatitis virus, Maraba virus exhibits improved safety and reduced neurovirulence while maintaining strong oncolytic potential. This review aims to comprehensively summarize the biological characteristics of the MG1 Maraba virus, its genetic development, mechanisms of action, and current preclinical and clinical applications as a novel oncolytic immunotherapeutic agent.<\/jats:p>","DOI":"10.3390\/v18060617","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:17:31Z","timestamp":1780467451000},"page":"617","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming Barriers to Clinical Translation: MG1 Maraba Virus as an Emerging Platform for Oncolytic Immunotherapy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-679X","authenticated-orcid":false,"given":"Tareq","family":"Abualfaraj","sequence":"first","affiliation":[{"name":"Department of Basic Medical Sciences, College of Medicine, Taibah University, Madinah 42353, Saudi Arabia"},{"name":"Health and Life Research Center, Taibah University, Madinah 42353, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OV.S154494","article-title":"Development and applications of oncolytic Maraba virus vaccines","volume":"7","author":"Pol","year":"2018","journal-title":"Oncolytic Virother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13058-016-0744-y","article-title":"Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment","volume":"18","author":"Roy","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e009443","DOI":"10.1136\/jitc-2024-009443","article-title":"Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling","volume":"12","author":"Armstrong","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"ref_7","first-page":"1","article-title":"Oncolytic viruses: A step into cancer immunotherapy","volume":"4","author":"Pol","year":"2012","journal-title":"Virus Adapt. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world\u2019s first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kaufman, H.L., Shalhout, S.Z., and Iodice, G. (2022). Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.834841"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma","volume":"18","author":"Bommareddy","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/mt.2009.154","article-title":"Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus","volume":"17","author":"Bridle","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/mt.2012.265","article-title":"HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy","volume":"21","author":"Bridle","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2010.103","article-title":"Identification of genetically modified maraba virus as an oncolytic rhabdovirus","volume":"18","author":"Brun","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ijc.30813","article-title":"Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma","volume":"141","author":"Selman","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eaao1641","DOI":"10.1126\/scitranslmed.aao1641","article-title":"Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy","volume":"10","author":"Roy","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virol.2006.10.026","article-title":"Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates","volume":"360","author":"Johnson","year":"2007","journal-title":"Virology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4269\/ajtmh.1984.33.999","article-title":"Carajas and Maraba viruses, two new vesiculoviruses isolated from phlebotomine sand flies in Brazil","volume":"33","author":"Tesh","year":"1984","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hassanzadeh, G., Naing, T., Graber, T., Jafarnejad, S.M., Stojdl, D.F., Alain, T., and Holcik, M. (2019). Characterizing Cellular Responses During Oncolytic Maraba Virus Infection. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030580"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/mt.2013.249","article-title":"Maraba virus as a potent oncolytic vaccine vector","volume":"22","author":"Pol","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/2326-6066.CIR-16-0162","article-title":"NK-cell recruitment is necessary for eradication of peritoneal carcinomatosis with an IL12-expressing Maraba virus cellular vaccine","volume":"5","author":"Alkayyal","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccr.2011.09.005","article-title":"Virus-Tumor Interactome Screen Reveals ER Stress Response Can Reprogram Resistant Cancers for Oncolytic Virus-Triggered Caspase-2 Cell Death","volume":"20","author":"Mahoney","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/mt.2010.98","article-title":"Potentiating cancer immunotherapy using an oncolytic virus","volume":"18","author":"Bridle","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-22-1471","article-title":"Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks","volume":"28","author":"Cillo","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/2162402X.2019.1674113","article-title":"Prognostic profiling of the immune cell microenvironment in Ewing\u2019s Sarcoma Family of Tumors","volume":"8","author":"Stahl","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Barr, T., Jennings, V.A., Roundhill, E.A., Baugh, R.T., Yamrali, M., Owston, H.E., McGonagle, D., Giannoudis, P.V., Caplen, N.J., and Khan, J. (2025). Oncolytic Maraba Virus MG1 Mediates Direct and Natural Killer Cell-Dependent Lysis of Ewing Sarcoma. Cancers, 17.","DOI":"10.1101\/2025.05.16.654440"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1038\/sj.onc.1203127","article-title":"PKR.; A sentinel kinase for cellular stress","volume":"18","author":"Williams","year":"1999","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1357-2725(98)00131-9","article-title":"eIF4E activity is regulated at multiple levels","volume":"31","author":"Raught","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"a032672","DOI":"10.1101\/cshperspect.a032672","article-title":"Noncanonical Translation Initiation in Eukaryotes","volume":"11","author":"Kwan","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/v7020739","article-title":"eIF4E as a Control Target for Viruses","volume":"7","author":"Montero","year":"2015","journal-title":"Viruses"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.biochem.73.030403.080419","article-title":"The molecular mechanics of eukaryotic translation","volume":"73","author":"Kapp","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1073\/pnas.111145798","article-title":"Molecular mechanisms of translation initiation in eukaryotes","volume":"98","author":"Pestova","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","article-title":"Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism","volume":"13","author":"Gingras","year":"1999","journal-title":"Genes. Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbagrm.2014.12.007","article-title":"Roles of the translation initiation factor eIF2\u03b1 serine 51 phosphorylation in cancer formation and treatment","volume":"1849","author":"Koromilas","year":"2015","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1128\/MCB.16.11.6295","article-title":"Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR","volume":"16","author":"Taylor","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/embj.201387344","article-title":"eIF5B employs a novel domain release mechanism to catalyze ribosomal subunit joining","volume":"33","author":"Kuhle","year":"2014","journal-title":"EMBO J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1128\/JVI.00115-11","article-title":"The herpes simplex virus 1 vhs protein enhances translation of viral true late mRNAs and virus production in a cell type-dependent manner","volume":"85","author":"Dauber","year":"2011","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1101\/gad.891101","article-title":"Internal ribosome entry sites in eukaryotic mRNA molecules","volume":"15","author":"Hellen","year":"2001","journal-title":"Genes Dev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrm1618","article-title":"Translational control in stress and apoptosis","volume":"6","author":"Holcik","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-4939-9794-7_19","article-title":"Considerations for Clinical Translation of MG1 Maraba Virus","volume":"2058","author":"Breitbach","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40425-019-0641-x","article-title":"Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer","volume":"7","author":"McGray","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1445459","DOI":"10.1080\/2162402X.2018.1445459","article-title":"Transforming the prostatic tumor microenvironment with oncolytic virotherapy","volume":"7","author":"Atherton","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/mto.2015.13","article-title":"Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis","volume":"2","author":"Tong","year":"2015","journal-title":"Mol. Ther. Oncolytics."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/mt.2014.60","article-title":"Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease","volume":"22","author":"Zhang","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1158\/1078-0432.CCR-12-3199","article-title":"Leukemia cell-rhabdovirus vaccine: Personalized immunotherapy for acute lymphoblastic leukemia","volume":"19","author":"Conrad","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-024-01580-3","article-title":"New strategies in soft tissue sarcoma treatment","volume":"17","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-10-2066","article-title":"Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas","volume":"17","author":"Sasaki","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9346","DOI":"10.1128\/JVI.00723-11","article-title":"Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: Rare resistance is overcome by blocking interferon pathways","volume":"85","author":"Paglino","year":"2011","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3892\/ijo.2012.1514","article-title":"Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus","volume":"41","author":"Atsumi","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1128\/MCB.24.16.7275-7283.2004","article-title":"EWS\/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3","volume":"24","author":"Prieur","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4161\/cc.7.2.5229","article-title":"A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature","volume":"7","author":"Hancock","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1200\/JCO.2020.38.15_suppl.11500","article-title":"Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012)","volume":"38","author":"Brennan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Z\u00f6llner, S.K., Amatruda, J.F., Bauer, S., Collaud, S., de \u00c1lava, E., DuBois, S.G., Hardes, J., Hartmann, W., Kovar, H., and Metzler, M. (2021). Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081685"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing Sarcoma: Current Management and Future Approaches Through Collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: Clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e26719","DOI":"10.1002\/pbc.26719","article-title":"Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas","volume":"65","author":"Spurny","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-25-0635","article-title":"Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas","volume":"31","author":"Kuo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ymthe.2020.01.027","article-title":"Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus","volume":"28","author":"Aref","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"M\u00fcller, L., Berkeley, R., Barr, T., Ilett, E., and Errington-Mais, F. (2020). Past, Present and Future of Oncolytic Reovirus. Cancers, 12.","DOI":"10.3390\/cancers12113219"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2015.88","article-title":"Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia","volume":"29","author":"Parrish","year":"2015","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/imm.13453","article-title":"Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity","volume":"166","author":"Wantoch","year":"2022","journal-title":"Immunology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrc1670","article-title":"Breast cancer metastasis: Markers and models","volume":"5","author":"Weigelt","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kaur, P., Nagaraja, G.M., Zheng, H., Gizachew, D., Galukande, M., Krishnan, S., and Asea, A. (2012). A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-120"},{"key":"ref_67","first-page":"1233","article-title":"Understanding and Treating Triple-Negative Breast Cancer","volume":"22","author":"Anders","year":"2008","journal-title":"Oncology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0960-9822(95)00180-1","article-title":"How does taxol stabilize microtubules?","volume":"5","author":"Arnal","year":"1995","journal-title":"Curr. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/gt.2010.121","article-title":"Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1","volume":"18","author":"Huang","year":"2011","journal-title":"Gene Ther."},{"key":"ref_70","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-09-0334","article-title":"Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication","volume":"15","author":"Prestwich","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/mt.2012.128","article-title":"Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine","volume":"20","author":"Lemay","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1525-0016(03)00120-5","article-title":"Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model","volume":"7","author":"Miller","year":"2003","journal-title":"Mol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri2817","article-title":"Prostate cancer as a model for tumour immunotherapy","volume":"10","author":"Drake","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/mt.2011.301","article-title":"ORFV: A novel oncolytic and immune stimulating parapoxvirus therapeutic","volume":"20","author":"Rintoul","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Granot, T., Venticinque, L., Tseng, J.C., and Meruelo, D. (2011). Activation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectors. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020598"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/gt.2009.161","article-title":"Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma","volume":"17","author":"Galivo","year":"2010","journal-title":"Gene Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0748-7983(05)80061-7","article-title":"Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease","volume":"21","author":"Deehan","year":"1995","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/bjs.1800751012","article-title":"Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses","volume":"75","author":"Sedman","year":"1988","journal-title":"Br. J. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1158\/0008-5472.CAN-12-1993","article-title":"Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells","volume":"73","author":"Tai","year":"2013","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e1512329","DOI":"10.1080\/2162402X.2018.1512329","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials","volume":"8","author":"Pol","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Flores Banda, J.S., Gangane, S., Raza, F., and Massarelli, E. (2025). Current development of therapeutic vaccines in lung cancer. Vaccines, 13.","DOI":"10.3390\/vaccines13020185"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e001387","DOI":"10.1136\/jitc-2020-001387","article-title":"In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity","volume":"9","author":"Jenner","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/6\/617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:23:49Z","timestamp":1780467829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/6\/617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":84,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["v18060617"],"URL":"https:\/\/doi.org\/10.3390\/v18060617","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}